Clinical Ink was founded in 2007 by the late Tommy Littlejohn, M.D. and Doug Pierce. Tommy and Doug passionately believed that their solution would revolutionize clinical research by eliminating paper source documents—the last hurdle to paperless clinical trials.
Long before the iPad, Tommy and Doug envisioned a tablet-based software application that would “look and feel” like paper source to the site user. However, while being as familiar as paper, this innovative solution would also capture, validate and share data electronically—providing cleaner data faster. Clinical Ink’s co-founders brought valuable perspectives and a unique mix of expertise to build an organization that could realize their vision. Tommy brought 20+ years of experience as a clinical investigator and Doug brought another 20+ years of experience running a medical forms publishing business.
From 2007-2010, Tommy’s experience as an active researcher (3,000+ studies) served as an anchor and filter through which all software decisions would pass. In this way, the impact on the site was always the pre-eminent factor. Doug’s experience with medical forms design was equally important in developing an intuitive user experience. Often, the application interface would be tested with actual site users. If the tablet wasn’t at least as fast and as easy to use as paper, the interface would be redesigned—always with the goal of reducing site workload.
Today, Tommy and Doug’s vision has become a reality as Clinical Ink continues to revolutionize clinical research. Clinical Ink remains committed to the founders’ goals of dramatically reducing the cost and complexity of clinical research for sites, sponsors and patients.
Ed Seguine, Chief Executive Officer
As Chief Executive Officer (CEO) of Clinical Ink, Ed Seguine brings more than years of experience as a clinical technology executive at Big Pharma and start-up organizations. Ed joined Clinical Ink in late 2009 with the goal of creating a company that would eliminate the problems caused by the current paper-based processes and technologies.
Prior to joining Clinical Ink, Mr. Seguine was General Manager, Trial Planning at Medidata Solutions, where he managed the acquisition integration activities and product positioning prior to the company’s IPO. He also served as CEO of Fast Track Systems where he oversaw the turn-around process and established the early commercial successes for a novel product that became the rationale for acquisition by Medidata Solutions. Prior to Fast Track, Ed was a founding manager of the Eli Lilly & Co. venture capital funds—e.Lilly and Lilly Bioventures—focusing on technology and biotech/device companies.
Ed has been intimately involved with key industry initiatives, including CDISC and eClinical Forum. He is a frequent presenter at industry events and publishes regularly. Ed earned an MBA from Indiana University-Bloomington and a bachelor’s degree in finance from Brigham Young University.
Doug Pierce, President & Co-Founder
Doug Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as President and Co-Founder, Mr. Pierce brings 20+ years of experience in digital forms technology and mobile data capture to lead the strategic direction, development and evolution of Clinical Ink’s eSource Suite.
Prior to Clinical Ink, Mr. Pierce co-founded Piermed, Inc., a medical documentation solutions company specializing in data capture for primary care settings. Offering an alternative to the inefficient data capture methods traditionally used by physicians, Mr. Pierce developed a series of electronic forms to effectively streamline medical data capture and retrieval. Under Mr. Pierce’s leadership, Piermed, Inc. grew from a small regional start-up into an established corporation with customers in 48 states.
A pioneer of eSource technology for the life sciences industry, Doug is noted for giving the first eSource presentation to the U.S. Food and Drug Administration in 2008. He earned a master’s degree and bachelor’s degree in philosophy from the University of Montana.
Kirk McPoyle, Chief Commercial Officer
As Chief Commercial Officer Kirk McPoyle brings 25 years of experience in pharmaceutical and healthcare management to his role. Kirks leads all Clinical Ink global sales activities to drive market adoption of the company’s industry-leading eSource and patient engagement products and solutions.
Mr. McPoyle joined Clinical Ink from Acurian – a patient recruitment organization – where as Senior VP of Business Development, he was responsible for leading the commercial team to sales and implementation excellence. During his tenure he created and implemented all commercial strategies, including: customer approach, pricing, proposals and contracting.
Prior to Acurian, Kirk held several roles at IMS Health, a leading provider of business intelligence for the pharmaceutical and healthcare industry. As VP of commercial operations for the Americas, he was responsible for executing the commercial strategy across the Americas, and overseeing both the sales operations group, and the development and orchestration of the organization’s customer loyalty program. Prior to IMS Health, Kirk held roles of increasing responsibility in sales, national account management/marketing, as well as senior management positions at TAP Pharmaceuticals.
Jonathan Andrus, Chief Operating Officer
As Chief Operating Officer, Jonathan Andrus leads Clinical Ink’s global data management and quality & compliance teams to help drug sponsors better leverage eSource data. With 20+ years of experience, Mr. Andrus brings extensive expertise developing eClinical services that integrate data and technology to help life science companies optimize study execution.
Mr. Andrus joined Clinical Ink from BioClinica where he led the eClinical Solutions Group to develop their current service offerings, including data management, quality management, implementation services and IWRS. While at BioClinica, Mr. Andrus built relationships and forged strategic partnerships with sponsors, CROs, regulatory bodies, technology developers and clinical research professionals. Prior to BioClinica, Mr. Andrus worked in pharmaceutical consulting and with CROs focused on quality, data management and validation.
An active thought leader, blogger and presenter, Jonathan served as chair of the Society for Clinical Data Management (SCDM) in 2008 and 2014 and currently serves as the society’s Treasurer. He is also an active member of DIA, ASQ, ACRO and CDISC. He earned his bachelor’s and master’s degrees from Temple University’s College of Liberal Arts and Graduate School of Pharmacy and is a Certified Quality Auditor (CQA) and Certified Clinical Data Manager (CCDM®).
Joe Alea, Chief Technology Officer
As Chief Technical Officer Joe Alea heads up all technology functions globally, playing a central role in the development and execution of the Company’s overall product strategy and success.
Mr. Alea has created enterprise and mission-critical systems for over 30 years with a philosophy that complex business problems deserve simple solutions that help drive adoption and utilization. He is known for delivering quality and timely products by creating effective teams and for following a disciplined engineering process.
Before Clinical Ink, Alea served as senior vice president at Medicity, as CTO and SVP at Curaspan Health Group, and was vice president of development at Oracle Health Sciences, through the acquisition of Phase Forward. He has also held senior executive positions at Princeton Softech, Davox, and McKesson.
Scott Miltenberger, Chief Financial Officer
As Chief Financial Officer, Scott Miltenberger leads Clinical Ink’s accounting, business planning and global financial operations. Mr. Miltenberger brings more than 20 years of financial management and technology industry experience, primarily in executive roles leading strategic global financial operations.
Prior to joining Clinical Ink, Mr. Miltenberger was Chief Financial Officer for GPX Enterprises (GPX), a private equity firm focused on the sponsorship, development and management of selected investments, where he helped lead the company through a period of rapid growth. Prior to GPX, Scott served as CFO for Elemica, a cloud-based software services company, where he led the company’s financial strategy, capital raising initiatives, and was instrumental in the organization’s M&A activities. Prior to Elemica, he served as the founding CFO for a venture-backed healthcare services company and held a senior financial role at Novacare Employee Services, where he helped position the company for its IPO. Scott began his career at Deloitte & Touche LLP.
In addition to being a Certified Public Accountant (CPA), Scott holds a master of business administration in finance from Villanova University and a bachelor’s degree in economics and business from Lafayette College. He is active in many local business and youth sports organizations.
Society for Clinical Research Sites
Clinical Data Interchange Standards Consortium
CCDM Industry Partner